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REDUCED COMPLEMENT 
ACTIVATION AND IMPROVED 
POSTOPERATIVE 
PERFORMANCE AFTER 
CARDIOPULMONARY 
BYPASS WITH HEPARIN- 
COATED CIRCUITS 
A randomized controlled triai that invoived 30 patients undergoing elective 
coronary artery bypass grafting was done to determine the effect of 
heparin-coated circuits and full heparinization  complement activation, 
neutrophil-mediated inflammatory response, and postoperative clinical 
recovery. Peak concentrations of terminal complement complex were 38% 
lower (p = 0.004) in 15 patients treated with heparin-coated circuits 
(median 775/zg/L, interquartile range 600 to 996) eompared with those in 
15 patients treated with uncoated circuits (median 1249/~g/L, interquartile 
range 988 to 1443). Although no significant intergroup differences in 
concentrations of polymorphonuclear neutrophil elastase were found, a 
positive correlation (ru = 0.74, p < 0.0007) was calcnlated between peak 
concentrations of terminal complement complex and polymorphonuclear 
neutrophii elastase. Differences in patient recovery were analyzed with use 
of a score composed of fluid balance, postoperative intubation time, and the 
difference between r ctal temperature and skin temperature. The score was 
significantly ower in patients treated with heparin-coated circuits (p = 
0.03), whereas its components showed no intergroup significance. We 
conclude that the use of heparin-coated circuits with full systemic hepa- 
rinization results in improved biocompatibility, as assessed by complement 
activation, and leads to an improved postoperative recovery of the patient. 
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T he use of extracorporeal circulation circuits still contributes to he morbidity of cardiac opera- 
tions. Exposure of blood to the artificial surfaces of 
the extracorporeal circuit during cardiopulmonary 
bypass (CPB) results in plasmatic and cellular acti- 
vation of the host defense mechanismJ Activation 
of the cornplement cascade during CPB takes place 
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predominantly through the alternative pathway and 
results in activation of C3, which in turn generates 
an amplifying C3 convertase complex. 2'3 These en- 
zymatic complexes activate the terminal comple- 
ment pathway with the formation of C5a and C5b-9 
or terminal complement complex (TCC). Deposi- 
tion of pore-forming TCC on erythrocytes during 
CPB has been associated with hemolysis and bond- 
age of TCC on granulocytes may result in activation 
of the latter. 4 Clinical studies have shown that the 
morbidity and the occurrence of adverse vents of 
CPB are associated with the degree of complement 
activation.», 6 In this regard, it has been suggested 
that the biocompatibility of extracorporeal circuits 
be assessed by the degree of complement activation, 
specifically TCC.  7' 8 
Heparin surface-coating of CPB circuits was orig- 
inally introduced to enable reduction or even elim- 
ination of systemic heparinization. With strict regu- 
lations to prevent low-flow areas in the circuit, 
low-dose heparinization has been practiced safely 
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for specific indications with significant reductions of 
blood loss and blood requirements. 9 Several clinical 
studies have demonstrated reduced complement 
activation and lower levels of inflammatory media- 
tors in patients treated with reduced systemic hep- 
arinization and heparin-coated circuits. 1°-13 How- 
ever, these studies did not report on improvements 
in the postoperative clinical recovery of the patients 
associated with a clear reduction in inflammatory 
mediators, which should be essential in the assess- 
ment of improved biocompatibility. 
The aim of this study was to determine whether 
the use of heparin-coated circuits and full systemic 
heparinization improves the biocompatibility of the 
circuit with respect o reduced complement activa- 
tion during CPB and whether this reduction corre- 
sponds with a reduction in leukocyte-mediated 
inflammatory response and an improved postoper- 
ative clinical recovery. Therefore we measured 
plasma levels of TCC and polymorphonuclear neu- 
trophil elastase (PMN elastase) during and after 
CPB. To quantitate the postoperative clinical recov- 
ery a carefully chosen score was used. This score is 
composed of a combination of clinical parameters 
representing the inflammatory response in the in- 
tensive care unit (ICU): the rectal and peripheral 
skin temperature, the fluid balance, and the intuba- 
tion time. 
Patients and methods 
Design of the study. A standardized group of 30 pa- 
tients undergoing elective first-time coronary artery by- 
pass grafting (CABG) was studied to minimize interfefing 
sources of blood activation. When significant changes can 
be determined in such a low-risk population, a more 
pronouneed effect might be expeeted in patients with 
high-risk conditions undergoing CPB. Inclusion criteria 
were left ventricular end-diastolic pressure less than 25 
mm Hg and aeetylsalicylic acid stopped for more than 3 
days. Patients with preoperative coagulopathy or impaired 
organ function other than myocardial ischemia nd those 
receiving antiinflammatory drugs were excluded. The pa- 
tients were randomly allocated to be treated with either a 
heparin-coated circuit (n = 15) or an uncoated circuit 
(n = 15). Physicians involved in patient care and biochem- 
ists were blinded for randomization. Informed consent 
was obtained from each patient and the study was ap- 
proved by the Medical Ethics Committee of the Free 
University Hospital. 
Anesthesia nd CPB. On the morning of the operation, 
patients received their usual early-morning dose of anti- 
anginal medication and lorazepam 5 mg. Anesthesia was 
induced with intravenous sufentanil citrate 3/xg/kg, pan- 
curonium bromide 0.1 mg/kg, and midazolam 0.1 mg/kg 
and maintained by supplemental doses of these drugs. 
Cefuroxime 1500 mg was given intravenously for infection 
prophylaxis. After endotracheal intubation, patients re- 
ceived mechanical ventilation of the lungs to normocapnia 
with an oxygen and air mixture. Radial artery and ther- 
modilution pulmonary artery catheters were placed for 
hemodynamic measurements and procurement of blood 
samples. 
The extracorporeal circulation circuit consisted of a 
soft-shell venous reservoir, roller pump, membrane oxy- 
genator (Univox, Baxter Healthcare Corp., Irvine, Calff.), 
arterial line filter, cardiotomy reservoir, and polyvinyl 
tubing system. In the heparin-coated group, all patts of 
the extracorporeal circuit were treated with surface- 
bonded heparin (Duraflo II, Baxter). The total priming 
volume of the system was 1400 ml and consisted of 1250 
ml lactated Ringer's olution, 100 ml 20% mannitol, 50 ml 
8.4% sodium bicarbonate, and 5000 IE heparin. For the 
performance of subtotal CPB, a standard cannulation 
technique was used with cannulas placed in the ascending 
aorta and right atrium (two-stage venous cannula). After 
systemic heparinization (300 IU/kg) was accomplished, 
CPB was initiated when the activated clotting time was 
longer than 400 seconds. The left ventricle was vented via 
the aortic root. Blood flora the pericardial cavity was 
collected in a cardiotomy reservoir and returned to the 
patient. The hematocrit value during CPB was maintained 
at 22% to 23%; if possible, autologous blood was taken 
ffom the patient from the venous cannula just before the 
onset of extracorporeal circulation. A nonpulsatile flow 
rate was maintained at 2.2 to 2.4 L.min -1 .m -2 and 
patients were cooled to 29 ° to 30°C nasopharyngeal 
temperature. After the aorta was crossclamped, all pa- 
tients received bigb-potassium (16 mmol/L), cold erystal- 
loid cardioplegic solution (800 to 1000 tal, 4 ° C) for 
myocardial protection. Distal anastomoses of the grafts 
were placed during aortic crossclamping, and proximal 
anastomoses were constructed after aortic crossclamp 
release and restored mechanical ventilation. Acid-base 
balance was managed according to the alpha-stat concept. 
Patients were weaned from CPB with the use of inotropic 
support if necessary. After termination of CPB, heparin 
was neutralized by an equal dose of protamine sulfate (3 
mg/kg). Autologous blood and residual volume flora the 
extracorporeal circuit were infused in the patient as 
first-choice fluid administration. 
Postoperative are. After the operation, all patients 
were transferred to the ICU, where they were treated 
according to a standardized protocol. Hemodynamic goals 
were heart rate 70 to 80 beats/min, mean arterial blood 
pressure 65 to 80 mm Hg, pulmonary artery wedge 
pressure 8 to 12 mm Hg, and cardiac index greater than 
2.5 L-min -1. m -2. The use of inotropic support was 
guided by the individual status of the patient. The fluid 
balance, the rectal temperature, and the peripheral tem- 
perature (measured on the back of the foot) were re- 
corded every hour. The peripheral circulation was consid- 
ered to be adequate if the difference between rectal 
temperature and peripheral skin temperature (AT) was 
less than 5 ° C. 
Patients received mechanical ventilation to normocap- 
nia and an arterial oxygen tension greater than 80 mm Hg 
with intermittent positive-pressure breathing and 5 cm 
H20 positive end-expiratory pressure. Detubation was 
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Table I. Patient characteristics and surgical data 
Uncoated Heparin-coated 
circuits circuits 
(n = 15) (n = 15) 
Age (yr) 58 _+ 2 60 _+ 2 
Mate/female 11/4 12/3 
BSA (m 2) 2.02 _+ 0.04 1.99 _+ 0.05 
LVEDP (mm Hg) 15 _+ 1 14 _+ 0.2 
Total heparin (mg/kg) 6.1 + 0.1 6.0 _+ 0.1 
Total protamine (mg/kg) 6.1 _+ 0.1 6.0 + 0.1 
CPB time (min) 100 _+ 8 107 _+ 6 
Distal anastomoses 4 (2-6) 3 (1-6) 
There were no significant differences between groups. Distal anastomoses 
are presented as median with range. The internal mammary artery was 
used in 11 patients in the uncoated group and in 13 patients in the 
heparin-coated group. BSA, Body surface area, LVEDP, left ventricular 
end-diastolic pressure; CPB time, duration of CPB. 
permitted if the following criteria were met: (1) the 
patient was awake and cooperative with a spontaneous 
respiration frequency 10 to 20 breaths/min, (2) positive- 
pressure support was less than 5 cm H20, (3) arterial 
oxygen tension was greater than 80 mm Hg, and (4) 
inspired oxygen fraction was less than 40%. The minimum 
required postoperative intubation time, that is, the mo- 
ment that all four criteria were fulfilled, was recorded and 
was independent of the medical decision to detubate the 
patient at that time. 
Basic intravenous fluid administration consisted of 
NaC1 0.9%. Modified fluid gelatin 4% (Netherlands Pro- 
duction Laboratory Blood Transfusion Requirements and 
Infusions, Emmer Compascuum, The Netherlands) and 
human albumin 20% (Central Laboratory Netherlands 
Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands) were added when the colloid oncotic pres- 
sure was less than 15 mm Hg. Packed red blood cells were 
infused when the hematocrit level was less than 26%. 
Blood loss and blood requirements were reeorded until 18 
hours after the operation. 
Blood sampling and processing. All blood samples 
were drawn from the radial artery catheter or the arterial 
site of the extracorporeal circulation circuit distal from the 
arterial ine filter and immediately immersed in crushed 
ice. After pla~elet-poor plasma was prepared, samples 
were stored at -70°C. Hematocrit value, leukocyte 
counts, and platelet counts were determined from all 
samples. Concentrations of TCC and PMN elastase were 
not corrected for dilution. 
Terminal complement complex. Two milliliters of blood 
was collected in tubes and anticoagulated with ethylene- 
dinitrotetra cetate before induction of anesthesia (base- 
line), after aortic crossclamp release, after termination of 
CPB, and 20 minutes after protamine infusion. Fluid 
phase C5b-9 complement complex concentrations were 
determined with use of an enzyme immunoassay accord- 
ing to protocol (Behringwerke AG Diagnostica, Marburg, 
Germany). 
PMN elastase. Two milliliters of blood was collected in 
tubes and anticoagulated with citrate before induction of 
anesthesia (baseline), after aortic crossclamp release, 
after termination of CPB, and 1 hour after patient arrival 
2000 
1500 
1000 
500 
TCC (pg/L) 
T ..... "0 
ù...4 .......... "~ ..... 
sc" -4- 
I I I I 
baseline after end after 
X-release CPB protamine 
Fig. 1. Concentrations of fluid-phase TCC in patients 
treated with uncoated circuits (dotted line) or heparin- 
coated circuits (solid line). Data presented as medians 
with interquartile range. X-release, crossclamp release; 
*p < 0.05 between groups; ×p < 0.005 compared with 
baseline values; ÷p < 0.05 compared with baseline values. 
in the ICU. PMN elastase concentrations were deter- 
mined with use of an activating immunization method 
(Merck Diagnostica, Darmstadt, Germany) with an auto- 
mated homogenous enzyme immunoassay (Hitachi 717 
selective analyzer, Boehringer, Mannheim, Germany). 
Data analysis. Data were stored and analyzed with the 
use of standard computer software (Statview 4.02, Abacus 
Concepts, Berkeley, Calif.). To quantitate the inflamma- 
tory response, a face validity-based score was applied. 14 
This "clinical performance score" is composed of the sum 
of (1) the total fluid balance until 18 hours after operation 
(measured uring the operation and every hour in the 
ICU), (2) the mean AT during the first 18 hours in the 
ICU (measured every 2 hours), and (3) time of fulfillment 
of detubation criteria divided by 4. In this way, all the 
components of the score have a comparable fange and 
therefore a cõmparable weight in the score. A higher 
score indicates a more pronounced inflammatory re- 
sponse. 
Comparisons between groups were assessed with un- 
paired two-tailed t tests. Nonparametric statistical meth- 
ods were used to analyze the skewed biochemical data 
(TCC and PMN elastase): comparisons within groups 
were assessed with the Wilcoxon signed-rank test and 
comparisons between groups with the Mann-Whitney U
test. Spearman's rank correlation (rs) was calculated when 
appropriate. A two-tailedp value <0.05 was considered to 
be statistically significant. Means plus or minus the stan- 
dard error of the mean are presented, unless otherwise 
stated. 
Results 
Demographic data and surgical data of both 
groups are listed in Table I. No complications 
occurred and all patients survived and were dis- 
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Fig. 2. Concentrations of PMN elastase in patients 
treated with uncoated circuits (dotted line) or heparin- 
coated circuits (solid line). Data presented as medians 
with interquartile fange. There were no differences be- 
tween groups at distinct sample moments. X-release, 
Crossclamp release; ×p < 0.005 compared with baseline 
values; +p < 0.05 compared with baseline values. 
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Fig. 4. Difference between rectal temperature and pe- 
ripheral skin temperature (AT) measured uring first 18 
hours after operation in patients treated with uncoated 
circuits (dotted line) or heparin-coated circuits (soIid line). 
Data presented as means plus or minus standard error of 
mean. *p < 0.05 between groups. 
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Fig. 3. Scatter diagram of pooled data of post-CPB peak 
levels of fluid-phase TCC and post-CPB peak levels of 
PMN elastase. 
charged from the ICU on the first postoperative day. 
Both groups demonstrated a significant increase in 
circulating levels of TCC during and after CPB 
compared with baseline values (Fig. 1), but no 
further increments were observed after administra- 
tion of protamine. Post-CPB peak levels of TCC 
were 38% lower in the heparin-coated group (775 
/zg/L, interquartile range 600 to 996) eompared with 
those in the uncoated group (1249/xg/L, interquar- 
tile range 988 to 1443, p = 0.004). In both groups, 
concentrations of PMN elastase were significantly 
higher at the end of CPB compared with baseline 
values (Fig. 2). Concentrations of PMN elastase 
tended to be higher in the uncoated group, with the 
greatest difference occurring during the ICU stay 
(p = 0.07). A positive correlation was found be- 
tween post-CPB peak levels of TCC and PMN 
elastase (Fig. 3, rs = 0.74, p = 0.0007). 
The course of/XT is presented in Fig. 4. During 
the first 4 hours in the ICU, AT was significantly 
higher in the uncoated group, and another 4 hours 
later AT was less than the desired 5°C in both 
groups. The clinical performance score and its com- 
ponents are depicted in Table II. A lower score (p = 
0.03) was calculated for the heparin-coated group, 
whereas none of the components were different 
among groups. There were no differences between 
groups" with respect to postoperative blood loss, 
blood requirements, hematocrit value, leukocyte 
count, or platelet count. Neither hemodynamic vari- 
ables nor gas exchange values yielded intergroup 
differcnces. The hemodynamic response to CPB was 
not influenced by protamine infusion. 
Discussion 
This study clearly demonstrated that the use of 
heparin-coated circuits resulted in reduced concen- 
trations of TCC during elective first-time CABG 
with normal heparinization. Moreover, the reduc- 
tion of complement activation corresponded with 
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improved postoperative r covery, as represented by 
a favorable clinical performance score in patients 
treated with heparin-coated circuits. 
In all patients ignificant increments in circulating 
TCC were observed, but at all sample points during 
and after CPB concentrations of TCC were signifi- 
cantly lower in patients treated with heparin-coated 
circuits. Additional activation of the complement 
cascade by heparin-protamine complexes, as ob- 
served by others, Is' 16 was not reflected in further 
increments of TCC levels after protamine infusion. 
Because we have solely incorporated measure- 
ments of the terminal complex of complement acti- 
vation, the mechanism by which the lower concen- 
trations of TCC with heparin-coated circuits 
occurred remains to be elucidated. Both surface- 
bound and fluid-phase heparin exhibit inhibitory 
irlterference with multiple steps in the complement 
cascade. 17 The inactivation of C3b is intensified by 
heparin, ~s and Maillet and associates 19postulated 
that heparin prevents the generation of the C3 
amplification convertase. Apart from the inhibitory 
capacity of heparin on activation of the alternative 
pathway, the lower TCC concentrations also might 
be explained by direct binding of TCC to the 
heparin coating, as proposed by Videm and associ- 
ates a° on the basis of in vitro studies. 
So far, complement studies that demonstrated a 
reduction of TCC with heparin-coated circuits were 
done in patients treated with reduced systemic he- 
parinization in combination with heparin coat- 
ing.10, 12, 13 Because complement activation is inhib- 
ited by both surface-bound and fluid-phase heparin, 
no conclusions can be made concerning an inhibi- 
tory effect on complement activation of heparin 
coating and reduced systemic heparinization i com- 
parison with routine heparinization and uncoated 
circuits. In the study presented here, an identical 
systemic heparinization protocol (3 mg/kg) for both 
heparin-coated and uncoated circuits was used, and 
clearly the inhibitory effect of heparin coating as the 
one discriminating variable on complement activa- 
tion could be determined. This means that in a 
routine setting of CABG with full heparinization, a 
reduction of complement activation can be obtained 
when heparin-coated circuits are applied. 
The diversity of inflammatory mediators identi- 
fied in connection with CPB makes it ditticult to 
determine their interaction or to define their role 
in the inttammatory esponse. Although an inhib- 
itory effect of heparin-coated circuits on neutro- 
phil activation could not be determined here, we 
Table II. Clinical performance score 
Uncoated Hepaffn-coated 
circuits circuits 
(n = 15) (n = 15) p Value 
(1) Fluid balance (L) 3.0 -+ 0.4 
(2) Extubation criteria (hr) 20.0 _+ 2.1 
(3) Mean AT (° C) 4.6 _+ 0.2 
Clinical pefformance score 12.6 _+ 0.8 
2.4 -+ 0.3 0.24 
17.4 --+ 1.2 0.30 
4.0 + 0.3 0.12 
10.7 -+ 0.4 0.03 
Clinical performance score = (1) + (2)/4 + (3). p Value denotes 
intergroup level of significance. Mean AT = mean difference between 
rectal and peripheral skin temperature in the ICU, measured every 2 hours 
until 18 hours after operation. 
demonstrated that 55% of the increase in PMN 
elastase could be explained by the increase in 
TCC. This is in agreement with previous findings 
that complement activation can up-regulate neu- 
trophils. 21-23 
Biocompatibility is defined as the ability of bio- 
materials to perform without a host response and 
usually is expressed by the levels of bioactive sub- 
stances encountered in the circulation after contact 
with the biomaterial. However, the clinical response 
to improved biocompatibility is difficult to assess in 
patients undergoing elective CABG, because these 
responses are usually mild. Instead of isolated clin- 
ical parameters, we propose the use of a scoring 
system as a clinical end point. The score is composed 
of three parameters with equal weight, all more or 
less related with an inflammatory response to CPB. 
The fluid balance might reflect edema formation, 
whereas the difference between rectal temperature 
and skin temperature presents he peripheral cir- 
culation. The actual moment of detubation ismerely 
a medical decision and is likely to flaw the score 
system. For that reason, we chose to record the 
moment at which standardized criteria for detuba- 
tion are fulfilled. The lower score of patients treated 
with heparin-coated circuits indicates that, even 
after low-risk CABG, the postoperative inflamma- 
tory response was attenuated. The difference be- 
tween rectal temperature and skin temperature was 
significantly higher in patients treated with uncoated 
circuits until 6 hours after operation. After that 
time, AT reached levels equal to those of the 
heparin-coating group. Early recovery of AT, as was 
observed in the heparin-coated group, might be 
particularly beneficial in patients with a compro- 
mised peripheral circulation. 
In conclusion, we demonstrated that the biocom- 
patibility of extracorporeal circulation circuits, as 
assessed by complement activation, can be improved 
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by the immobilization of heparin on the inner 
surface of these circuits. A favorable clinical perfor- 
mance score was observed in patients treated with 
heparin-coated circuits. The potential usefulness 
and clinical relevance of heparin-coated circuits 
might be greatest when they are incorporated in 
protocols dealing with early recovery and reduction 
of intensive care requirements after cardiac opera- 
tions, specifically in patients with high-risk factors. 
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